查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1421685

重症肌无力治疗市场、份额、规模、趋势、行业分析报告：按药物类别、按诊断、按治疗、按分销渠道、按地区、按细分市场、预测，2024-2032 年

Myasthenia Gravis Disease Treatment Market Share, Size, Trends, Industry Analysis Report, By Drug Class ; By Diagnosis, By Treatment, By Distribution Channel; By Region; Segment Forecast, 2024 - 2032
出版日期: | 出版商: Polaris Market Research | 英文 116 Pages | 商品交期: 最快1-2个工作天内

价格

根据Polaris Market Research的最新研究，到2032年，全球重症肌无力治疗市场规模预计将达到23.2亿美元。 该报告提供了对当前市场动态的详细洞察，并对未来市场成长进行了分析。

重症肌无力是一种自体免疫神经肌肉疾病，免疫系统攻击神经和肌肉之间的连接，导致肌肉无力和疲劳。

由于多种因素，重症肌无力 (MG) 治疗市场近年来稳定成长。 其中包括诊断数量的增加、对疾病的更深入了解以及治疗方法的进步。 製药公司也正在投资研发，以推出更有效且副作用更少的创新疗法。 随着生物製剂和分子标靶治疗的出现，对更安全、更有效的治疗的需求预计将继续推动全球重症肌无力治疗市场的成长。

COVID-19 大流行对重症肌无力 (MG) 疾病市场产生了重大影响。 由于医疗保健系统集中在 COVID-19 患者，导致诊断和治疗延误，MG 面临挑战。 然而，大流行加速了远距医疗和远端监控的使用，为重症肌无力患者咨询医疗保健专业人员提供了重要工具，同时最大限度地减少了病毒暴露。 儘管有这种干扰，製药业仍在继续开发重症肌无力的新疗法，为改善治疗方案带来了希望。

此外，国家医学图书馆 2021 年 6 月发表的一项研究强调了冠状动脉疾病 (CAD) 对全球健康的重大影响。 光是 CAD 每年就导致约 61 万人死亡，占估计死亡人数的四分之一，是美国的第一大死因。 随着 CAD 发生率的增加，对有效的冠状动脉支架装置的需求不断增长，以满足这一紧迫的医疗需求。 因此，预计这一因素将在预测期内推动冠状动脉支架的需求。

重症肌无力市场报告重点

  • 2022 年，IVIG 细分市场在重症肌无力市场中占据最大的销售份额。 静脉注射免疫球蛋白治疗 (IVIg) 涉及输注从健康捐赠者获得的免疫球蛋白抗体。 人们发现这种医疗程序对于暂时调节免疫系统和控制重症肌无力 (MG) 症状非常有效。
  • 在预测期内，医院部门占据了最高的市场份额。 医院药局透过分发和使用各种药物，在重症肌无力 (MG) 的治疗中发挥重要作用。 随着重症肌无力病例数的增加，越来越多的患者在医院接受治疗，增加了医院药局对重症肌无力专用药物的需求。
  • 2022 年，北美占据最大市场。 重症肌无力（MG）在北美有显着的盛行率，且北美在治疗中占有重要地位。 该地区强大的医疗基础设施有助于识别和管理大量重症肌无力患者，这引起了製药公司和研究人员的兴趣。 此外，有弹性的医疗报销框架有效扩大了许多昂贵的重症肌无力治疗的覆盖范围，增加了患者的可及性并促进及时干预。
  • 亚太地区是肌无力治疗市场成长最快的地区。 该市场的成长受到多种因素的推动，其中最引人注目的是公共和私人机构的合作努力。 这些努力主要集中在开发和传播神经肌肉疾病的有效治疗方法。 此外，透过教育活动和资讯传播努力提高大众对神经肌肉疾病的认识也推动了市场的扩张。

目录

第一章简介

第 2 章执行摘要

第三章研究方法

第四章全球重症肌无力治疗市场洞察

  • 重症肌无力治疗 - 产业概况
  • 重症肌无力治疗市场动态
    • 推动者和机会
      • 全球治疗方法和治疗选择的改进推动了市场成长
      • 医疗基础建设费用上涨推动市场成长
    • 抑制因素和挑战
      • 高昂的处理成本阻碍了市场成长
  • 杵分析
  • 重症肌无力治疗产业的趋势
  • 价值链分析
  • COVID-19 感染的影响分析

第 5 章全球重症肌无力治疗市场（依药物类别）

  • 主要发现
  • 简介
  • IVIg
  • 单株抗体
  • 免疫抑制剂
  • 胆碱酯□抑制剂
  • 皮质类固醇

第 6 章全球重症肌无力治疗市场（依诊断）

  • 主要发现
  • 简介
  • 验血
  • 电气诊断
  • 依酚铵测试

第七章全球重症肌无力治疗市场（依治疗）

  • 主要发现
  • 简介
  • 手术
  • 药品
  • 造血干细胞移植

第 8 章全球重症肌无力治疗市场（依通路）

  • 主要发现
  • 简介
  • 网路药局
  • 医院药房
  • 零售药局

第 9 章全球重症肌无力治疗市场（按地区）

  • 主要发现
  • 简介
    • 2019-2032 年重症肌无力治疗市场评估，地区
  • 重症肌无力治疗市场 - 北美
    • 北美：重症肌无力治疗市场，依药物类别，2019-2032 年
    • 北美：重症肌无力治疗市场，依通路划分，2019-2032 年
    • 北美：2019-2032 年重症肌无力治疗市场（依诊断）
    • 北美：重症肌无力治疗市场（依治疗方式），2019-2032 年
    • 重症肌无力治疗市场 - 美国
    • 重症肌无力治疗市场 - 加拿大
  • 重症肌无力治疗市场 - 欧洲
    • 欧洲：2019-2032 年重症肌无力治疗市场（依药物类别）
    • 欧洲：重症肌无力治疗市场，依通路划分，2019-2032 年
    • 欧洲：2019-2032 年重症肌无力治疗市场（依诊断）
    • 欧洲：重症肌无力治疗市场（依治疗方式），2019-2032 年
    • 重症肌无力治疗市场 - 英国
    • 重症肌无力治疗市场 - 法国
    • 重症肌无力治疗市场 - 德国
    • 重症肌无力治疗市场 - 义大利
    • 重症肌无力治疗市场 - 西班牙
    • 重症肌无力治疗市场 - 荷兰
    • 重症肌无力治疗市场 - 俄罗斯
  • 重症肌无力治疗市场 - 亚太地区
    • 亚太地区：重症肌无力治疗市场，依药物类别，2019-2032 年
    • 亚太地区：重症肌无力治疗市场（依通路），2019-2032 年
    • 亚太地区：2019-2032 年重症肌无力治疗市场（依诊断）
    • 亚太地区：重症肌无力治疗市场（依治疗方式），2019-2032 年
    • 重症肌无力治疗市场 - 中国
    • 重症肌无力治疗市场 - 印度
    • 重症肌无力治疗市场 - 日本
    • 重症肌无力治疗市场 - 马来西亚
    • 重症肌无力治疗市场 - 印度尼西亚
    • 重症肌无力治疗市场 - 韩国
  • 重症肌无力治疗市场 - 中东和非洲
    • 中东和非洲：2019-2032 年重症肌无力治疗市场（依药物类别）
    • 中东与非洲：重症肌无力治疗市场（依通路），2019-2032 年
    • 中东与非洲：2019-2032 年重症肌无力治疗市场（依诊断）
    • 中东与非洲：重症肌无力治疗市场（依治疗方式），2019-2032 年
    • 重症肌无力治疗市场 - 沙乌地阿拉伯
    • 重症肌无力治疗市场 - 南非
    • 重症肌无力治疗市场 - 以色列
    • 重症肌无力治疗市场 - 阿联酋
  • 重症肌无力治疗市场 - 拉丁美洲
    • 拉丁美洲：重症肌无力治疗市场，依药物类别，2019-2032 年
    • 拉丁美洲：重症肌无力治疗市场，依通路划分，2019-2032 年
    • 拉丁美洲：2019-2032 年重症肌无力治疗市场（依诊断）
    • 拉丁美洲：重症肌无力治疗市场（依治疗方式），2019-2032 年
    • 重症肌无力治疗市场 - 墨西哥
    • 重症肌无力治疗市场 - 巴西
    • 重症肌无力治疗市场 - 阿根廷

第10章竞争态势

  • 扩张与收购分析
    • 放大
    • 收购
  • 伙伴关係/协作/协议/揭露

第十一章公司简介

  • AbbVie Inc.
  • Alexion Pharmaceuticals, Inc.
  • Bausch Health Companies Inc.（formerly Valeant Pharmaceuticals）
  • Bristol-Myers Squibb Company（now part of Bristol Myers Squibb）
  • Grifols, S.A.
  • Mylan N.V.（now part of Viatris Inc.）
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Roche Holdings AG（including its subsidiary, Genentech）
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
Product Code: PM4026

The global myasthenia gravis disease treatment market size is expected to reach USD 2.32 billion by 2032, according to a new study by Polaris Market Research. The report "Myasthenia Gravis Disease Market Share, Size, Trends, Industry Analysis Report, By Drug Class (IVIg, Monoclonal Antibodies, Immunosuppressants, Cholinesterase Inhibitors, Corticosteroids); By Diagnosis, By Treatment, By Distribution Channel; By Region; Segment Forecast, 2024 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Myasthenia gravis is an autoimmune neuromuscular disorder that causes muscle weakness and fatigue due to the immune system attacking the connection between nerves and muscles.

The market for treating Myasthenia Gravis (MG) has been growing steadily in recent years due to several factors. There has been an increase in the number of diagnoses, better understanding of the disease, and advancements in treatment options. Pharmaceutical companies have also invested in research and development to introduce innovative therapies that offer more effectiveness and fewer side effects. With the emergence of biologics and targeted therapies, the demand for safer and more efficient treatments is expected to continue driving the growth of the global MG treatment market.

The COVID-19 pandemic had a significant impact on the Myasthenia Gravis (MG) disease market. MG faced challenges due to the healthcare system's focus on COVID-19 patients, causing delays in diagnosis and treatment. However, the pandemic accelerated the use of telemedicine and remote monitoring, which provided crucial tools for MG patients to consult with healthcare providers while minimizing virus exposure. The pharmaceutical industry continued to develop novel therapies for MG despite disruptions, offering hope for improved treatment options.

Additionally, a study published in the National Library of Medicine in June 2021 highlighted the significant impact of coronary artery disease (CAD) on global health. CAD alone is responsible for approximately 610,000 deaths annually, accounting for an estimated one in four deaths and making it the foremost cause of mortality in the United States. With the incidence of CAD rising, there is a growing demand for effective coronary stent devices to address this pressing medical need. Consequently, this factor is projected to drive the demand for coronary stents throughout the forecast period.

Myasthenia Gravis Disease Market Report Highlights

  • In 2022, the IVIg segment held the largest revenue share in the myasthenia gravis disease market. Intravenous Immunoglobulin (IVIg) treatment involves the infusion of immunoglobulin antibodies obtained from healthy donors. This medical procedure has been found to be highly effective in temporarily regulating the immune system and managing the symptoms of Myasthenia Gravis (MG).
  • The hospital segment accounted for the highest market share during the forecast period. Hospital pharmacies play a vital role in managing Myasthenia Gravis (MG) through the distribution and application of various medications. As MG cases increase, more patients seek treatment in hospitals, leading to a higher demand for MG-specific drugs in hospital pharmacies.
  • In 2022, North America dominated the largest market. Myasthenia gravis (MG) exhibits a significant prevalence in North America, positioning it as a key player in the landscape of treatment. The region's robust healthcare infrastructure facilitates the identification and management of a substantial number of MG cases, drawing the interest of pharmaceutical firms and researchers alike. Furthermore, the resilient healthcare reimbursement framework effectively extends coverage to numerous costly MG treatments, enhancing their accessibility for patients and promoting prompt intervention.
  • The Asia-Pacific region accounted for the fastest growth in the myasthenia disease treatment market. The market's growth is driven by various factors, notably the concerted efforts of both public and private entities. These endeavors primarily focus on advancing and distributing effective treatments for neuromuscular disorders. Moreover, the market's expansion is fueled by increasing public awareness of neuromuscular conditions, supported by educational campaigns and information dissemination initiatives.
  • The global key market players include: AbbVie Inc., Alexion Pharmaceuticals, Inc., Bausch Health Companies Inc., Bristol-Myers Squibb Company, Grifols, S.A., Mylan N.V., Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Roche Holdings AG, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd.

Polaris Market Research has segmented the myasthenia disease treatment market report based on drug class, diagnosis, treatment, distribution channel, and region:

Myasthenia Gravis Disease Treatment, Drug Class Outlook (Revenue - USD Billion, 2019 - 2032)

  • IVIg
  • Monoclonal Antibodies
  • Immunosuppressants
  • Cholinesterase Inhibitors
  • Corticosteroids

Myasthenia Gravis Disease Treatment, Diagnosis Outlook (Revenue - USD Billion, 2019 - 2032)

  • Blood Tests
  • Electrodiagnosis
  • Edrophonium Test

Myasthenia Gravis Disease Treatment, Treatment Outlook (Revenue - USD Billion, 2019 - 2032)

  • Surgery
  • Medication
  • HSCT

Myasthenia Gravis Disease Treatment, Distribution Channel Outlook (Revenue - USD Billion, 2019 - 2032)

  • Online Pharmacies
  • Hospital Pharmacies
  • Retail Pharmacies

Myasthenia Gravis Disease Treatment, Regional Outlook (Revenue - USD Billion, 2019 - 2032)

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Myasthenia Gravis Disease Treatment Market Insights

  • 4.1. Myasthenia Gravis Disease Treatment - Industry Snapshot
  • 4.2. Myasthenia Gravis Disease Treatment Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Improvement in therapies and treatment options across the Globe will Facilitate market growth
      • 4.2.1.2. Inflation of healthcare infrastructure bill bolster market growth
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. High treatment cost will hamper on the market growth
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTLE Analysis
  • 4.5. Myasthenia Gravis Disease Treatment Industry Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Myasthenia Gravis Disease Treatment Market, by Drug Class

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • 5.3. IVIg
    • 5.3.1. Global Myasthenia Gravis Disease Treatment Market, by IVIg, by Region, 2019-2032 (USD Billion)
  • 5.4. Monoclonal Antibodies
    • 5.4.1. Global Myasthenia Gravis Disease Treatment Market, by Monoclonal Antibodies, by Region, 2019-2032 (USD Billion)
  • 5.5. Immunosuppressants
    • 5.5.1. Global Myasthenia Gravis Disease Treatment Market, by Immunosuppressants, by Region, 2019-2032 (USD Billion)
  • 5.6. Cholinesterase Inhibitors
    • 5.6.1. Global Myasthenia Gravis Disease Treatment Market, by Cholinesterase Inhibitors, by Region, 2019-2032 (USD Billion)
  • 5.7. Corticosteroids
    • 5.7.1. Global Myasthenia Gravis Disease Treatment Market, by Corticosteroids, by Region, 2019-2032 (USD Billion)

6. Global Myasthenia Gravis Disease Treatment Market, by Diagnosis

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
  • 6.3. Blood Tests
    • 6.3.1. Global Myasthenia Gravis Disease Treatment Market, by Blood Tests, by Region, 2019-2032 (USD Billion)
  • 6.4. Electrodiagnosis
    • 6.4.1. Global Myasthenia Gravis Disease Treatment Market, by Electrodiagnosis, by Region, 2019-2032 (USD Billion)
  • 6.5. Edrophonium Test
    • 6.5.1. Global Myasthenia Gravis Disease Treatment Market, by Edrophonium Test, by Region, 2019-2032 (USD Billion)

7. Global Myasthenia Gravis Disease Treatment Market, by Treatment

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • 7.3. Surgery
    • 7.3.1. Global Myasthenia Gravis Disease Treatment Market, by Surgery, by Region, 2019-2032 (USD Billion)
  • 7.4. Medication
    • 7.4.1. Global Myasthenia Gravis Disease Treatment Market, by Medication, by Region, 2019-2032 (USD Billion)
  • 7.5. HSCT
    • 7.5.1. Global Myasthenia Gravis Disease Treatment Market, by HSCT, by Region, 2019-2032 (USD Billion)

8. Global Myasthenia Gravis Disease Treatment Market, by Distribution Channel

  • 8.1. Key Findings
  • 8.2. Introduction
    • 8.2.1. Global Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
  • 8.3. Online Pharmacies
    • 8.3.1. Global Myasthenia Gravis Disease Treatment Market, by Online Pharmacies, by Region, 2019-2032 (USD Billion)
  • 8.4. Hospital Pharmacies
    • 8.4.1. Global Myasthenia Gravis Disease Treatment Market, by Hospital Pharmacies, by Region, 2019-2032 (USD Billion)
  • 8.5. Retail Pharmacies
    • 8.5.1. Global Myasthenia Gravis Disease Treatment Market, by Retail Pharmacies, by Region, 2019-2032 (USD Billion)

9. Global Myasthenia Gravis Disease Treatment Market, by Geography

  • 9.1. Key findings
  • 9.2. Introduction
    • 9.2.1. Myasthenia Gravis Disease Treatment Market Assessment, By Geography, 2019-2032 (USD Billion)
  • 9.3. Myasthenia Gravis Disease Treatment Market - North America
    • 9.3.1. North America: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
    • 9.3.2. North America: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 9.3.3. North America: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
    • 9.3.4. North America: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
    • 9.3.5. Myasthenia Gravis Disease Treatment Market - U.S.
      • 9.3.5.1. U.S.: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 9.3.5.2. U.S.: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.3.5.3. U.S.: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
      • 9.3.5.4. U.S.: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
    • 9.3.6. Myasthenia Gravis Disease Treatment Market - Canada
      • 9.3.6.1. Canada: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 9.3.6.2. Canada: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.3.6.3. Canada: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
      • 9.3.6.4. Canada: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • 9.4. Myasthenia Gravis Disease Treatment Market - Europe
    • 9.4.1. Europe: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
    • 9.4.2. Europe: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 9.4.3. Europe: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
    • 9.4.4. Europe: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
    • 9.4.5. Myasthenia Gravis Disease Treatment Market - UK
      • 9.4.5.1. UK: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 9.4.5.2. UK: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.4.5.3. UK: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
      • 9.4.5.4. UK: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
    • 9.4.6. Myasthenia Gravis Disease Treatment Market - France
      • 9.4.6.1. France: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 9.4.6.2. France: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.4.6.3. France: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
      • 9.4.6.4. France: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
    • 9.4.7. Myasthenia Gravis Disease Treatment Market - Germany
      • 9.4.7.1. Germany: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 9.4.7.2. Germany: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.4.7.3. Germany: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
      • 9.4.7.4. Germany: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
    • 9.4.8. Myasthenia Gravis Disease Treatment Market - Italy
      • 9.4.8.1. Italy: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 9.4.8.2. Italy: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.4.8.3. Italy: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
      • 9.4.8.4. Italy: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
    • 9.4.9. Myasthenia Gravis Disease Treatment Market - Spain
      • 9.4.9.1. Spain: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 9.4.9.2. Spain: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.4.9.3. Spain: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
      • 9.4.9.4. Spain: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
    • 9.4.10. Myasthenia Gravis Disease Treatment Market - Netherlands
      • 9.4.10.1. Netherlands: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 9.4.10.2. Netherlands: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.4.10.3. Netherlands: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
      • 9.4.10.4. Netherlands: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
    • 9.4.11. Myasthenia Gravis Disease Treatment Market - Russia
      • 9.4.11.1. Russia: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 9.4.11.2. Russia.: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.4.11.3. Russia: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
      • 9.4.11.4. Russia: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • 9.5. Myasthenia Gravis Disease Treatment Market - Asia Pacific
    • 9.5.1. Asia Pacific: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
    • 9.5.2. Asia Pacific: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 9.5.3. Asia Pacific: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
    • 9.5.4. Asia Pacific: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
    • 9.5.5. Myasthenia Gravis Disease Treatment Market - China
      • 9.5.5.1. China: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 9.5.5.2. China.: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.5.5.3. China: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
      • 9.5.5.4. China: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
    • 9.5.6. Myasthenia Gravis Disease Treatment Market - India
      • 9.5.6.1. India: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 9.5.6.2. India.: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.5.6.3. India: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
      • 9.5.6.4. India: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
    • 9.5.7. Myasthenia Gravis Disease Treatment Market - Japan
      • 9.5.7.1. Japan: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 9.5.7.2. Japan.: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.5.7.3. Japan: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
      • 9.5.7.4. Japan: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
    • 9.5.8. Myasthenia Gravis Disease Treatment Market - Malaysia
      • 9.5.8.1. Malaysia: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 9.5.8.2. Malaysia.: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.5.8.3. Malaysia: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
      • 9.5.8.4. Malaysia: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
    • 9.5.9. Myasthenia Gravis Disease Treatment Market - Indonesia
      • 9.5.9.1. Indonesia: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 9.5.9.2. Indonesia.: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.5.9.3. Indonesia: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
      • 9.5.9.4. Indonesia: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
    • 9.5.10. Myasthenia Gravis Disease Treatment Market - South Korea
      • 9.5.10.1. South Korea: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 9.5.10.2. South Korea.: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.5.10.3. South Korea: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
      • 9.5.10.4. South Korea: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • 9.6. Myasthenia Gravis Disease Treatment Market - Middle East & Africa
    • 9.6.1. Middle East & Africa: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
    • 9.6.2. Middle East & Africa: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 9.6.3. Middle East & Africa: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
    • 9.6.4. Middle East & Africa: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
    • 9.6.5. Myasthenia Gravis Disease Treatment Market - Saudi Arabia
      • 9.6.5.1. Saudi Arabia: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 9.6.5.2. Saudi Arabia: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.6.5.3. Saudi Arabia: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
      • 9.6.5.4. Saudi Arabia: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
    • 9.6.6. Myasthenia Gravis Disease Treatment Market - South Africa
      • 9.6.6.1. South Africa: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 9.6.6.2. South Africa: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.6.6.3. South Africa: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
      • 9.6.6.4. South Africa: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
    • 9.6.7. Myasthenia Gravis Disease Treatment Market - Israel
      • 9.6.7.1. Israel: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 9.6.7.2. Israel: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.6.7.3. Israel: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
      • 9.6.7.4. Israel: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
    • 9.6.8. Myasthenia Gravis Disease Treatment Market - UAE
      • 9.6.8.1. UAE: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 9.6.8.2. UAE: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.6.8.3. UAE: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
      • 9.6.8.4. UAE: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • 9.7. Myasthenia Gravis Disease Treatment Market - Latin America
    • 9.7.1. Latin America: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
    • 9.7.2. Latin America: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 9.7.3. Latin America: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
    • 9.7.4. Latin America: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
    • 9.7.5. Myasthenia Gravis Disease Treatment Market - Mexico
      • 9.7.5.1. Mexico: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 9.7.5.2. Mexico: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.7.5.3. Mexico: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
      • 9.7.5.4. Mexico: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
    • 9.7.6. Myasthenia Gravis Disease Treatment Market - Brazil
      • 9.7.6.1. Brazil: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 9.7.6.2. Brazil: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.7.6.3. Brazil: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
      • 9.7.6.4. Brazil: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
    • 9.7.7. Myasthenia Gravis Disease Treatment Market - Argentina
      • 9.7.7.1. Argentina: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 9.7.7.2. Argentina: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.7.7.3. Argentina: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
      • 9.7.7.4. Argentina: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)

10. Competitive Landscape

  • 10.1. Expansion and Acquisition Analysis
    • 10.1.1. Expansion
    • 10.1.2. Acquisitions
  • 10.2. Partnerships/Collaborations/Agreements/Exhibitions

11. Company Profiles

  • 11.1. AbbVie Inc.
    • 11.1.1. Company Overview
    • 11.1.2. Financial Performance
    • 11.1.3. Product Benchmarking
    • 11.1.4. Recent Development
  • 11.2. Alexion Pharmaceuticals, Inc.
    • 11.2.1. Company Overview
    • 11.2.2. Financial Performance
    • 11.2.3. Product Benchmarking
    • 11.2.4. Recent Development
  • 11.3. Bausch Health Companies Inc. (formerly Valeant Pharmaceuticals)
    • 11.3.1. Company Overview
    • 11.3.2. Financial Performance
    • 11.3.3. Product Benchmarking
    • 11.3.4. Recent Development
  • 11.4. Bristol-Myers Squibb Company (now part of Bristol Myers Squibb)
    • 11.4.1. Company Overview
    • 11.4.2. Financial Performance
    • 11.4.3. Product Benchmarking
    • 11.4.4. Recent Development
  • 11.5. Grifols, S.A.
    • 11.5.1. Company Overview
    • 11.5.2. Financial Performance
    • 11.5.3. Product Benchmarking
    • 11.5.4. Recent Development
  • 11.6. Mylan N.V. (now part of Viatris Inc.)
    • 11.6.1. Company Overview
    • 11.6.2. Financial Performance
    • 11.6.3. Product Benchmarking
    • 11.6.4. Recent Development
  • 11.7. Novartis AG
    • 11.7.1. Company Overview
    • 11.7.2. Financial Performance
    • 11.7.3. Product Benchmarking
    • 11.7.4. Recent Development
  • 11.8. Pfizer Inc.
    • 11.8.1. Company Overview
    • 11.8.2. Financial Performance
    • 11.8.3. Product Benchmarking
    • 11.8.4. Recent Development
  • 11.9. Regeneron Pharmaceuticals, Inc.
    • 11.9.1. Company Overview
    • 11.9.2. Financial Performance
    • 11.9.3. Product Benchmarking
    • 11.9.4. Recent Development
  • 11.10. Roche Holdings AG (including its subsidiary, Genentech)
    • 11.10.1. Company Overview
    • 11.10.2. Financial Performance
    • 11.10.3. Product Benchmarking
    • 11.10.4. Recent Development
  • 11.11. Takeda Pharmaceutical Company Limited
    • 11.11.1. Company Overview
    • 11.11.2. Financial Performance
    • 11.11.3. Product Benchmarking
    • 11.11.4. Recent Development
  • 11.12. Teva Pharmaceutical Industries Ltd.
    • 11.12.1. Company Overview
    • 11.12.2. Financial Performance
    • 11.12.3. Product Benchmarking
    • 11.12.4. Recent Development

List of Tables

  • Table 1 Global Myasthenia Gravis Disease Treatment Market, by Drug Class, by Region, 2019-2032 (USD Billion)
  • Table 2 Global Myasthenia Gravis Disease Treatment Market, by Diagnosis, by Region, 2019-2032 (USD Billion)
  • Table 3 Global Myasthenia Gravis Disease Treatment Market, by Treatment, by Region, 2019-2032 (USD Billion)
  • Table 4 Global Myasthenia Gravis Disease Treatment Market, by Distribution Channel, by Region, 2019-2032 (USD Billion)
  • Table 5 Myasthenia Gravis Disease Treatment Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Table 6 North America: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 7 North America: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
  • Table 8 North America: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 9 North America: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 10 U.S.: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 11 U.S.: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
  • Table 12 U.S.: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 13 U.S.: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 14 Canada: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 15 Canada: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
  • Table 16 Canada: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 17 Canada: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 18 Europe: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 19 Europe: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
  • Table 20 Europe: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 21 Europe: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 22 Germany: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 23 Germany: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
  • Table 24 Germany: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 25 Germany: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 26 France: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 27 France: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
  • Table 28 France: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 29 France: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 30 UK: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 31 UK: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
  • Table 32 UK: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 33 UK: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 34 Italy: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 35 Italy: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
  • Table 36 Italy: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 37 Italy: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 38 Netherlands: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 39 Netherlands: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
  • Table 40 Netherlands: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 41 Netherlands: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 42 Spain: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 43 Spain: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
  • Table 44 Spain: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 45 Spain: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 46 Russia: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 47 Russia: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
  • Table 48 Russia: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 49 Russia: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 50 Asia Pacific: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 51 Asia Pacific: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
  • Table 52 Asia Pacific: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 53 Asia Pacific: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 54 China: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 55 China: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
  • Table 56 China: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 57 China: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 58 Japan: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 59 Japan: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
  • Table 60 Japan: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 61 Japan: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 62 India: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 63 India: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
  • Table 64 India: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 65 India: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 66 Indonesia: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 67 Indonesia: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
  • Table 68 Indonesia: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 69 Indonesia: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 70 Malaysia: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 71 Malaysia: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
  • Table 72 Malaysia: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 73 Malaysia: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 74 South Korea: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 75 South Korea: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
  • Table 76 South Korea: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 77 South Korea: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 78 Latin America: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 79 Latin America: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
  • Table 80 Latin America: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 81 Latin America: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 82 Brazil: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 83 Brazil: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
  • Table 84 Brazil: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 85 Brazil: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 86 Mexico: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 87 Mexico: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
  • Table 88 Mexico: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 89 Mexico: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 90 Argentina: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 91 Argentina: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
  • Table 92 Argentina: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 93 Argentina: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 94 Middle East & Africa: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 95 Middle East & Africa: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
  • Table 96 Middle East & Africa: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 97 Middle East & Africa: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 98 UAE: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 99 UAE: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
  • Table 100 UAE: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 101 UAE: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 102 Saudi Arabia: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 103 Saudi Arabia: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
  • Table 104 Saudi Arabia: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 105 Saudi Arabia: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 106 South Africa: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 107 South Africa: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
  • Table 108 South Africa: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 109 South Africa: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 110 Israel: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 111 Israel: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
  • Table 112 Israel: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 113 Israel: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)

List of Figures

  • Figure 1. Global Myasthenia Gravis Disease Treatment Market, 2019-2032 (USD Billion)
  • Figure 2. Integrated Ecosystem
  • Figure 3. Research Methodology: Top-Down & Bottom-Up Distribution Channel
  • Figure 4. Market by Geography
  • Figure 5. Porter's Five Forces
  • Figure 6. Market by Drug Class
  • Figure 7. Global Myasthenia Gravis Disease Treatment Market, by Drug Class, 2021 & 2030 (USD Billion)
  • Figure 8. Market by Distribution Channel
  • Figure 9. Global Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2021 & 2030 (USD Billion)
  • Figure 10. Market by Diagnosis
  • Figure 11. Global Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2021 & 2030 (USD Billion)
  • Figure 12. Market by Treatment
  • Figure 13. Global Myasthenia Gravis Disease Treatment Market, by Treatment, 2021 & 2030 (USD Billion)